医学
检测点注意事项
随机对照试验
糖尿病
梅德林
临床试验
研究设计
重症监护医学
荟萃分析
糖尿病管理
急诊医学
内科学
2型糖尿病
病理
内分泌学
社会学
法学
社会科学
政治学
作者
Lubna A. Al‐Ansary,Andrew Farmer,Jennifer Hirst,Nia Roberts,Paul Glasziou,Rafael Perera,Christopher P. Price
出处
期刊:Clinical Chemistry
[Oxford University Press]
日期:2011-03-03
卷期号:57 (4): 568-576
被引量:79
标识
DOI:10.1373/clinchem.2010.157586
摘要
BACKGROUND The measurement of hemoglobin A1c (Hb A1c) is employed in monitoring of patients with diabetes. Use of point-of-care testing (POCT) for Hb A1c results at the time of the patient consultation potentially provides an opportunity for greater interaction between patient and caregiver, and more effective care. OBJECTIVE To perform a systematic review of current trials to determine whether POCT for Hb A1c, compared with conventional laboratory testing, improves outcomes for patients with diabetes. METHODS Searches were undertaken on 4 electronic databases and bibliographies from, and hand searches of, relevant journal papers. Only randomized controlled trials were included. The primary outcome measures were change in Hb A1c and treatment intensification. Metaanalyses were performed on the data obtained. RESULTS Seven trials were found. There was a nonsignificant reduction of 0.09% (95% CI −0.21 to 0.02) in the Hb A1c in the POCT compared to the standard group. Although data were collected on the change in proportion of patients reaching a target Hb A1c of <7.0%, treatment intensification and heterogeneity in the populations studied and how measures were reported precluded pooling of data and metaanalysis. Positive patient satisfaction was also reported in the studies, as well as limited assessments of costs. CONCLUSIONS There is an absence of evidence in clinical trial data to date for the effectiveness of POCT for Hb A1c in the management of diabetes. In future studies attention to trial design is needed to ensure appropriate selection and stratification of patients, collection of outcome measures, and action taken upon Hb A1c results when produced.
科研通智能强力驱动
Strongly Powered by AbleSci AI